We noticed you are on our AU page. Want to switch regions? Choose from the options:

Pancreatic Cancer


This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

Trial overview


Pancreatic cancer


 MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease.

Eligibility criteria

To be considered for the study you must meet the following criteria:

  • Adults, aged between 18-75 years 
  • histologic confirmation of pancreatic adenocarcinoma 
  •  Any of the following: 
    • T3 (tumour >4 cm)
    • Extrapancreaticextension 
    • Node positive (Stage IIB)
    • Borderlineresectablepancreatic cancer or 
    • Locally advanced pancreatic cancer
  • ECOG 0-1 
  • Tumour size <70mm 
  • No evidence of metastasis

Study details

Arm A: Control (40 patients): Standard of care chemotherapy.

Arm B: Investigational (80 patients): Standard of care chemotherapy with the addition of SBRT.

Further information

For more information regarding this clinical trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.